CytoResc:CytoSorb 救治 COVID-19 细胞因子风暴重症患者随机对照试验方案结构化摘要
本研究为一项多中心、前瞻性、开放标签、随机、1:1 平行对照的 IIb 期先导试验,计划在德国约 10 个 ICU 纳入约 80–100 例 SARS-CoV-2 PCR 阳性、CRP≥100 mg/l、PCT<2 ng/l 且出现血管麻痹性休克的重症患者,比较标准治疗联合 CytoSorb 血液吸附与单纯标准治疗的疗效,主要终点为血管麻痹性休克缓解时间。
要点
- CytoSorb 通过吸附细胞因子可能稳定 COVID-19 合并血管麻痹性休克患者的血流动力学。
- 主要终点为血管麻痹性休克缓解时间(无需血管升压药至少 8 小时维持 MAP≥65mmHg)。
- 使用抗生素者每次更换 CytoSorb 滤器后需追加一次抗生素剂量以防药物浓度不足。
核心结论
- 假设在疑似高炎症和休克的重症 COVID-19 患者中体外清除细胞因子可稳定血流动力学并改善预后。
研究设计与样本
- IIb 期、多中心、前瞻性、开放标签、随机、1:1 平行组先导研究,比较附加 CytoSorb 与不含 CytoSorb 的标准治疗。
- 计划从德国 7 个参与中心的 ICU(约 10 个 ICU)招募约 80–100 例患者(每组 40–50 例),未进行正式样本量计算。
- 纳入 18–80 岁、SARS-CoV-2 PCR 阳性、CRP≥100 mg/l、PCT<2 ng/l 且疑似细胞因子风暴(去甲肾上腺素>0.2 μg/min/kg 维持 MAP≥65mmHg)的患者。
- 随机化由柏林 Charité 临床试验中心通过 secuTrial® 电子系统完成,按中心分层、区组大小为 4。
- 临床医生和患者不设盲,统计学家接收盲态数据集进行分析。
关键数值与推荐
- 主要结局为血管麻痹性休克缓解时间(定义为无需血管升压药至少 8 小时以维持 MAP≥65mmHg),以天计。
- 次要结局包括入组后 7 天死亡率、出院前死亡率、第 1 天和第 3 天 IL-6 测量值、机械通气需求、机械通气持续时间、ICU 住院时间、CytoSorb 开始后第 1/2/3 天儿茶酚胺剂量及急性肾损伤。
- 疑似或证实的细菌性血管麻痹性休克原因为禁忌症。
- 入组标准后 24 小时内随机,干预组通过 Shaldon 导管接受 CytoSorb 治疗 3–7 天,每 24 小时更换滤器。
- 每纳入 10 例患者/随机组后进行安全性评估。
临床怎么用
- 对于 COVID-19 合并高炎症和血管麻痹性休克的重症患者,可考虑在标准治疗基础上附加 CytoSorb 血液吸附。
- 使用 CytoSorb 期间若患者接受抗生素,每次更换滤器后应追加一次抗生素剂量以避免浓度不足。
局限性
- 本研究为开放标签设计,临床医生和患者不设盲。
- 作为先导研究未进行正式样本量计算,计划样本量较小。
- 试验状态为招募尚未开始(方案版本 2020 年 4 月 24 日)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Approximately 8 - 10 % of COVID-19 patients present with a serious clinical course and need for hospitalization, 8% of hospitalized patients need ICU-treatment. Currently, no causal therapy is available and treatment is purely supportive. The main reason for death in critically ill patients is acute respiratory failure. However, in a number of patients a severe hyperinflammatory response with excessively elevated proinflammatory cytokines causes vasoplegic shock resistant to vasopressor therapy. A new polystyrene-based hemoadsorber (CytoSorb®, Cytosorbents Inc., New Jersey, USA) has been shown to adsorb effectively cytokines and other middle molecular weight toxins this way reducing their blood concentrations. This has been routinely used in clinical practice in the EU for other conditions where a cytokine storm occurs and an observational study has just been completed on COVID-19 patients. We hypothesized that the extracorporeal elimination of cytokines in critically ill COVID-19 patients with suspected hyperinflammation and shock may stabilize hemodynamics and improve outcome. The primary endpoint is time until resolution of vasoplegic shock, which is a well implemented, clinically relevant endpoint in critical care studies. TRIAL DESIGN: Phase IIb, multicenter, prospective, open-label, randomized, 1:1 parallel group pilot study comparing the additional use of "CytoSorb" to standard of care without "CytoSorb". PARTICIPANTS: Patients are recruited from the Intensive Care Units (ICUs) of 7 participating centers in Germany (approximately 10 ICUs). All patients aged 18- 80 with positive polymerase chain reaction (PCR) test for SARS-CoV-2, a C-reactive protein (CRP) ≥ 100 mg/l, a Procalcitonin (PCT) < 2 ng/l, and suspected cytokine storm defined via a vasoplegic shock (Norepinephrine > 0.2 μg/min/kg to achieve a Mean Arterial Pressure ≥ 65mmHg). Patients are included irrespective of indication for renal replacement therapy. Suspected or proven bacterial cause for vasoplegic shock is a contraindication. INTERVENTION AND COMPARATOR: Within 24 hours after meeting the inclusion criteria patients will be randomized to receive either standard of care or standard of care and additional "CytoSorb" therapy via a shaldon catheter for 3-7 days. Filter exchange is done every 24 hours. If patients receive antibiotics, an additional dose of antibiotics is administered after each change of "CytoSorb" filter in order to prevent underdosing due to "CytoSorb" treatment. MAIN OUTCOMES: Primary outcome is time to resolution of vasoplegic shock (defined as no need for vasopressors for at least 8 hours in order to sustain a MAP ≥ 65mmHg) in days. Secondary outcomes are 7 day mortality after fulfilling the inclusion criteria, mortality until hospital discharge, Interleukin-6 (IL-6) measurement on day 1 and 3, need for mechanical ventilation, duration of mechanical ventilation, duration of ICU-stay, catecholamine dose on day 1/2/3 after start of "CytoSorb" and acute kidney injury. RANDOMIZATION: An electronic randomization will be performed using the study software secuTrial® administered by the Clinical Study Center (CSC) of the Charité - Universitätsmedizin Berlin, Germany. Randomization is done in blocks by 4 stratified by including center. BLINDING (MASKING): The trial will be non-blinded for the clinicians and patients. The statistician will receive a blinded data set, so that all analyses will be conducted blinded. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): As this is a pilot study with the goal to examine the feasibility of the study design as well as the intervention effect, no formal sample size calculation was conducted. A total number of approximately 80-100 patients is planned (40-50 patients per group). Safety assessment is done after the inclusion of each 10 patients per randomization group. TRIAL STATUS: Please see the study protocol version from April 24 2020. Recruitment of patients is still pending. TRIAL REGISTRATION: The study was registered on April 27 2020 in the German Registry of Clinical Trials (DRKS) under the number DRKS00021447. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Stockmann H, Keller T, Büttner S, et al. CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 32586396. doi:10.1186/s13063-020-04501-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。